Statin use and breast cancer survival – a Swedish nationwide study

BMC Cancer

Table 4 Breast cancer related death and overall death in relation to statin use following breast cancer diagnosis^a

	Breast cancer related death					Overall death
Post-diagnostic statin use	Events	Person years	HR	95% Confidence Intervals	P-value	Events	Person years	HR	95% Confidence Intervals	P-value
Any statin use
No (n = 20,503)	2245	86,856	–	–		3811	99,102
Yes (n = 4358)	412	17,715	0.83	0.75–0.93	0.001	848	21,340	0.89	0.82–0.96	0.003
Daily statin dose
–
log (1 + ddd) (n = 93,595)	2657	10,4571^b	0.93	0.91 – 0.95	< 0.001	4659	12,0442	0.96	0.95–0.97	< 0.001
Daily statin dose by solubility
Lipophilic log(1 + ddd)			0.93	0.91–0.96	< 0.001			0.96	0.95–0.97	< 0.001
Hydrophilic log(1 + ddd)			0.93	0.89–0.98	0.002			0.96	0.93–0.99	0.003
Other log(1 + ddd)			0.99	0.84–1.17	0.93			1.07	0.97–1.16	0.24

^aThe Cox regression age at diagnosis, stage and diabetes took into account
^bIn the analysis of defined daily statin dose, the number of person years has been calculated for all subjects included without regard to treatment status. The same goes for the number of events

ISSN: 1471-2407